1. **DISCUSSION**: Please discuss whether there are sufficient data to support a finding that Arymo ER (morphine sulfate extended-release tablets) has properties that can be expected to deter abuse, commenting on support for abuse-deterrent effects for each of the three possible routes of abuse:
   a. Oral
   b. Nasal
   c. Intravenous

2. **VOTE**: If approved, should Arymo ER be labeled as an abuse-deterrent product by the oral route of abuse?

3. **VOTE**: If approved, should Arymo ER be labeled as an abuse-deterrent product by the nasal route of abuse?

4. **VOTE**: If approved, should Arymo ER be labeled as an abuse-deterrent product by the intravenous route of abuse?

5. **VOTE**: Should Arymo ER be approved for the proposed indication, management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate?